Alternatives to Atomwise

SYNTHIA™ Retrosynthesis software, developed by computer scientists and coded by chemists, allows scientists to quickly and easily navigate novel and innovative pathways for novel and previously published target molecules. You can quickly and efficiently scan hundreds pathways to identify the best options for your needs. Discover the most cost-effective route to your target molecule with the latest visualization and filtering features. You can easily customize the search parameters to eliminate or highlight reactions, reagents, or classes of molecules. Explore innovative and unique syntheses to build your desired molecule. Easy to generate a list for starting materials that are commercially available for your synthesis. ISO/IEC 27001 Information Security Certification will guarantee the confidentiality, integrity and protection of your data.

AIDDISON™, a drug discovery software, combines the power and efficiency of artificial intelligence (AI), computer-aided design (CADD), and machine learning (ML) to provide a valuable toolkit that can be used for medicinal chemistry. It is a unified platform that integrates all aspects of virtual screening, including ligand-based design and structure-based design. It also supports methods for in silico lead optimization and discovery.

BIOiSIMTM, a revolutionary 'virtual drug engine', is the first-in-class tool that allows drug developers to narrow down the number drugs that have potential value in treating or curing specific diseases or illnesses. We offer a variety of translational-based solutions that can be customized for your clinical and pre-clinical programs. All of these solutions are based on our BIOiSIMTM platform, which is a proven and validated platform for small molecules, large molecule, and viruses. Our models are built using data from thousands upon thousands of compounds across seven species, which gives them a robustness that is rare in the industry. The platform is focused on human outcomes and has at its core a translatability tool that transforms insights across species. The BIOiSIMTM platform is available before preclinical animal trials begin, which allows for earlier insights and saves on expensive outsourced experimentation.

We are a biotechnology company in clinical stage. We decode biology by integrating technological innovations across biology and chemistry to industrialize drug discovery. CRISPR genome editing and synthetic Biology allow for greater control over biology. Advanced robotics allows for reliable automation of complex laboratory research on an unprecedented scale. Neural network architectures allow for iterative analysis and inference from large, complex, in-house data sets. Cloud solutions increase the flexibility of high-performance computation. To build a next-generation biopharmaceutical business, we are using new technology to create virtuous learning cycles around datasets. A synchronized combination hardware, software, and data that is used to industrialize drug discovery. Redefining the traditional drug discovery process. One of the most extensive, broadest, and deepest pipelines in any technology-enabled drug company.

Artificial Intelligence and RNA sequencing (RNA–seq data) are both a necessity and a way to develop therapeutics that target splicing mistakes. Machine learning allows us to quickly identify new splicing mistakes and design therapeutic compounds to correct them. SpliceCore, our AI platform for RNA therapeutics research, is what we call SpliceCore. This technology platform was specifically designed for the analysis and interpretation of RNA sequencing data. It can identify, validate and test hypothetical drug targets quicker than traditional methods. Our proprietary database of over 5 million potential RNA-splicing errors is the heart of SpliceCore. It is the world's largest database of splicing mistakes and is used to test all RNA sequencing data that is submitted for analysis. Scalable cloud computing allows us to process large amounts of RNA sequencing data efficiently at a higher speed and lower cost, thereby exponentially accelerating therapeutic innovation.

Advanced molecular modeling can transform drug discovery and materials research. Our physics-based computational platform combines differentiated solutions for predictive modelling, data analytics, collaboration, and collaboration to allow rapid exploration of chemical space. Our platform is used by industry leaders around the world for drug discovery and materials science in fields such as aerospace, energy, semiconductors and electronics displays. The platform powers our drug discovery efforts, from target identification through hit discovery to lead optimization. It also powers our research collaborations to create novel medicines for critical public healthcare needs. Our team includes more than 150 Ph.D. scientists. This allows us to invest heavily in R&D.

The process of bringing a new drug to market, from the initial step to the final market introduction can be time-consuming, expensive, and highly regulated. It can take up to a decade. Final success depends on early access to accurate analytical results that are fast enough to make the right decisions during development and minimize late attrition. Today's drug development relies heavily on a rational approach. Typically, identifying the biological target is the first step. To identify the most promising candidates, it is necessary to have a deep understanding about their properties. Finding the most promising lead molecules can be a daunting task once a biological target is established. Lead discovery is typically the identification of potential drug candidates, either small organic molecules or biologic assembly with therapeutic potential.

BioNeMo, an AI-powered cloud service for drug discovery and framework, is built on NVIDIA NeMo Megatron. It is used to train and deploy large biomolecular Transformer AI models at supercomputing scale. The service provides pre-trained large language models (LLMs), native support for common file types for proteins, DNA, and chemistry, as well as data loaders for SMILES molecular structures and FASTA amino acid and nucleotide sequencings. You can also download the BioNeMo framework to run on your own infrastructure. ESM-1, which is based on Meta AI’s state-of the-art ESM-1b and ProtT5 respectively, are transformer-based protein-language models that can be used for learning embeddings for tasks such as property prediction and protein structure. BioNeMo will offer OpenFold, a deep-learning model for 3D structure prediction and novel protein sequences.

Clara's domain specific tools, AI pretrained models, accelerated applications, and accelerated AI applications are enabling AI advances in many fields, including medical device, imaging, drug discovery and genomics. Holoscan allows you to explore the entire pipeline of medical device deployment and development. With the NVIDIA IGX Developer Kits, you can build containerized AI apps using the Holoscan SDK. The NVIDIA IGX SDK includes pre-trained AI model, healthcare-specific acceleration libraries and reference applications for medical devices.

The biopharmaceutical market is complex today. There are growing demands for better specificity and safety, new treatment classes, and more complex mechanisms of disease. To keep up with this complexity, we need to have a better understanding of therapeutic behavior. Simulation and modeling provide unique opportunities to explore biological and physical processes down to the atomic levels. This can be used to guide physical experimentation and accelerate the discovery and development process. BIOVIA Discovery Studio brings together more than 30 years of peer reviewed research and world-class in-silico techniques like molecular mechanics and free energy calculations. It also allows for biotherapeutics developmentability and other related topics into one environment. It gives researchers a complete toolkit to explore the nuances in protein chemistry and to catalyze the discovery of small and big molecule therapeutics, from Target ID to Lead Optimizement.

We combine clinical and experimental data with machine learning to improve precision medicine and navigate human disease biology. Contingent AI™, a patent-pending technology, understands data relationships to provide sophisticated insights. We tackle data bias by iterating upon machine learning models that are based on decisions made during the feature engineering and pre-processing stages. We use zebrafish, cell, and other phenotypic animals models to validate in-silico predictions in in vivo experiments. We also genetically modify them in vitro to improve translation. We quickly incorporate new data into machine learning models by using active learning and computer vision on validated models of cardiac, central nervous system, and rare disorders. We quickly incorporate new data into machine learning models by using active learning and computer vision with validated models of cardiac, central nervous system, and rare disorders.

AutoDock is a set of automated docking tools. It predicts how small molecules, such sub- or drug candidates, will bind to a receptor with a known 3D structure. It has been improved over the years to add new functionalities and multiple engines were developed. AutoDock 4 is the current version, and AutoDock Vina is the latest. AutoDock-GPU is an accelerated version that runs hundreds of times faster than the original single CPU docking code. AutoDock 4 is actually composed of two main programs. Autodock docks the ligand to a list of grids that describe the target protein. Autogrid pre-calculates the grids. The atomic affinity grids can also be visualized. This can be used to help organic synthetic chemists create better binders.

Rare diseases are often poorly understood and only a small amount of information is available to support drug discovery programs. Healnet, an AI platform that analyzes millions of data points related to drug and disease, helps overcome these challenges. It identifies novel connections that could lead to new treatment options. We can simultaneously run multiple stages at scale by applying frontier technologies throughout the discovery and development process. It's a simple model that can be used by almost all pharmaceutical companies. One disease, one target and one drug. The next generation in drug discovery is AI-powered and parallel. The key three paradigms of drug discovery are combined.

Site-Identification by Ligand Competitive Saturation generates 3D maps (FragMaps), showing interaction patterns for chemical functional group with your target molecule. Site-Identification through Ligand Competitive Saturation generates 3D maps, (FragMaps), of interaction patterns for chemical functions groups with your target molecule. SILCS reveals the intricacies and provides tools to optimize ligand scaffolds through qualitative and quantitative binding pocket insights. This allows for faster and more effective drug design. SILCS employs multiple small molecule probes that have different functional groups and explicit solvent modeling to perform protein target mapping. Visualize positive interactions with the target macromolecule. Get insights to design better binding agents with the best functional groups.

To drive precision medicine programs that work, pharmaceutical companies require comprehensive genomic information. However, decisions are often made with only 10% of the data available. Genomenon provides 100% of the data. ProdigyTM Patient Landscapes are a cost-effective and efficient natural history research solution for pharmaceuticals. They enhance insights from retrospective and prospective health data to support the development rare disease therapies. Genomenon uses an AI-driven approach to deliver a thorough and expert assessment of all patients in the medical literature in a fraction time. Get a complete overview of every genomic biomarker in the medical literature. Every scientific assertion is supported with empirical evidence from medical literature. Identify all genetic drivers and determine which variants are pathogenic according ACMG clinical standards.

VeraChem LLC was established in 2000 to advance computer-aided drug discovery. These methods are implemented in high-performance software and provide comprehensive support to users. This is a key strategy of VeraChem LLC for product development. Current VeraChem software capabilities include host-guest and protein-ligand binding affinity prediction, fast calculation and computation of partial atomic charges for druglike compounds, computation and force of energies and forces using all the most commonly used empirical force field, automatic generation and generation of alternate resonance forms for drug-like substances, conformational search using the powerful Tork algorithm and automatic detection and removal of topological and 3D-molecular symmetries. VeraChem's software packages were built from a modular code base.

InSilicoTrials.com, a web-based platform that allows users to create and simulate computational models and simulations. There are many easy-to-use tools in silico. The platform is primarily for users in the medical device and pharmaceutical industries. In silico tools for medical devices allow computational testing in different biomedical areas such as radiology, orthopedics, and cardiovascular during product development, validation, and design. The platform offers access to in-silico tools for the pharmaceutical industry, which can be used at all stages of drug discovery and development. It also covers a variety of therapeutic areas. The only cloud-platform built on crowdscience makes it easy to access validated models and reduce your R&D expenses. There is a growing list of models that can be used on a pay-per-use basis.

StarDrop™, a comprehensive suite of integrated software, delivers the best in silico technology within a highly visual interface. StarDrop™, which allows seamless flow between the latest data, predictive modeling, and decision-making regarding the next round or synthesis, improves the speed, efficiency and productivity of the discovery process. A balance of different properties is essential for successful compounds. StarDrop™, which guides you through the multi-parameter optimization challenge, helps you target compounds with the highest chance of success. It also saves you time and resources by allowing you to synthesize fewer compounds and test them less often.

Genedata Biologics®, streamlines the discovery of biotherapeutics. This includes bispecifics and ADCs as well as TCRs, CARs-Ts, CARs-Ts, CARs, and AAVs. It integrates all discovery workflows, making it the most popular platform in the industry. This allows you to focus on innovation and is the most widely used. A first-in-class platform that digitalizes biotherapeutic discovery accelerates research. The platform simplifies complex R&D processes by allowing for the creation, tracking, testing, and evaluation of novel biotherapeutics drugs. It can work with any format: antibodies, bi- and multi-specifics as well as ADCs, novel scaffolds, therapeutic proteins, and engineered therapeutic cell line such CAR-T cells and TCRs. Genedata Biologics acts as a central data backbone that integrates all R&D processes. This includes library design, immunizations, selections, panning, molecular Biology, screening, protein engineering and expression, as well as candidate development and manufacturability assessment.

Scitara DLX™ provides a fast connectivity infrastructure for any instrument used in life science laboratories. It is fully compliant and auditable, and can be accessed from any cloud-based platform. Scitara™, a universal digital data network, connects all instruments, resources, apps, and software within the laboratory. The cloud-based platform, which is fully auditable, connects all data sources in the lab, allowing data to flow freely across multiple endpoints. Scientists can now spend their time on scientific research and not waste it trying to solve data problems. DLX corrects and curates flight data to support the creation of precise, structured data models that feed AI/ML systems. This supports a successful digital transformation strategy for the pharma and biopharma sectors. The ability to access scientific data allows for faster decision-making and drug discovery, which helps bring drugs to market quicker.

LiveDesign is an enterprise information platform that allows teams to collaborate, design, experiment, analyze, track, and report in one central platform. You can capture ideas and model data. Create and store virtual compounds in a central database. Use advanced models to prioritize new designs. Integrate biological data and model results from federated corporate databases. Use sophisticated cheminformatics for faster analysis and development of compounds. Advanced physics-based methods are combined with machine learning techniques to quickly improve prediction accuracy. Remote team members can collaborate in real-time. You can collaborate with remote team members to share ideas, test, revise, or advance chemical series without losing sight of your work.

Makya is a user-friendly SaaS-based platform for AI-driven drug design focusing on Multi-Parametric Optimization. It allows the design of novel compounds that are easy to make in accordance with a multiobjective blueprint at unprecedented speeds, performance and diversity. Makya has multiple generative algorithms that cover different use cases, from hit discovery to lead optimizing: fine-tuning to find optimal solutions in your chemical space according to your project blueprint; novelty to find new ideas of high novelty for rescaffolding/hit discoveries; forward to design a focused collection of compounds easily accessible using commercial starting materials. The new Makya 3D Module enhances the user-experience and scientific utility of Makya. Makya 3D offers a wide range of 3D modeling capabilities in both ligand and structure-based pipelines. You can now use these 3D scores to guide generation natively within Makya.

BC platforms uses the latest science, unique technology capabilities and strategic partnerships to accomplish our mission of revolutionizing drug discovery, personalizing care, and transforming medicine. Modular, flexible platform that integrates healthcare data. Open analytics framework seamlessly combines the most innovative methods, technology developments and analytics in one platform. Superior security: ISO 27001 certified and GDPR and HIPAA compliant. A complete product portfolio allows modern healthcare systems to fully embrace personalized medicine. Scalable deployments allow for a robust start and large-scale healthcare operation. Our unique toolbox enables faster translation of research insights into clinical practice. Our unique toolbox helps reduce risk, increase your pipeline value, and advance enterprise data strategy. We remove the barriers to data access and enable rapid insight generation.

Our immunotherapy approach starts with our understanding of antigens. We also know which neoantigens will be present on cells by Human leukocyte antigen molecules. This will allow us to identify the ones that will be transcribed and translated. Gritstone EDGETM is our machine-learning-based platform that enables us to accomplish this. It is difficult to develop cancer immunotherapies that include tumor specific neoantigens. Tumors can have hundreds of mutations. However, only a small number of these mutations result in true tumor-specific antigens. We used EDGE's new integrated neural network architecture to train it with millions of data points from hundreds tumor and normal tissue samples taken from patients of different ancestries.

DNAnexus Apollo™, accelerates precision drug discovery through collaboration that draws critical insights from omics data. Precision drug discovery requires the collection and analysis of large volumes of clinical and omics data. These data sets are extremely rich, but many legacy and home-grown informatics tools cannot handle their complexity and size. Silos, insufficient collaboration tools, and complex regulatory and security requirements can all hinder precision medicine programs. DNAnexus Apollo™, which supports precision drug discovery programs, empowers scientists and clinicians to analyze and explore omics and clinical data in a single environment built on a robust and scalable cloud platform. Apollo allows them to share data, tools and analyses securely with peers and colleagues from all over the world, regardless of whether they are on another floor or another continent.

InformAI is a healthcare company that focuses on AI solutions for medical diagnosis at the point of care and improving radiologist productivity. The Texas Medical Center is the largest medical center complex in the world. We developed our AI-enabled image classifications and patient outcome predictors. InformAI, along with its partners, is changing the way healthcare is delivered. InformAI partners with leading medical imaging companies, national physician groups, and renowned healthcare organizations to create solutions that improve patient outcomes. Our team includes leaders in healthcare, medicine, and artificial intelligence. InformAI Sinus Image Classifier was built using a 3D convolutional neural net (CNN), which is trained on radiology-validated 3D CT scan image libraries that contain 6 million images.

Use AI to accelerate the journey from bench-research and laboratory insights to life-changing therapies. Reduce your reading time to minutes and gain up to 90% more research productivity. With a high-precision and high-accuracy research, you can cut through the noise to navigate the ever-growing amount of scientific literature. Save time, reduce bias, and increase the odds of discovering novel things. Explore disease biology in depth and discover advanced targets. Causaly’s high-precision graph of knowledge consolidates evidence from millions publications, allowing for unbiased, deep scientific exploration. You can navigate cause-and effect relationships in biology without being an expert. Discover hidden connections by viewing all scientific documents. Causaly’s powerful AI machine is able to read millions of published biomedical publications in order to support better research and decision-making.

Eidogen-Sertanty’s Target Informatics platform (TIP), is the first global structural informatics system. It enables researchers to examine the druggable genome from an structural perspective. TIP increases the rapidly expanding body experimental protein structure information and transforms structure based drug discovery from an inefficient, data-scarce discipline to a high-throughput science with rich data. TIP is a tool that bridges the knowledge gap between bioinformatics (bioinformatics) and cheminformatics. It provides drug discovery researchers with a knowledge bank of information that is both unique and highly complementary to existing bio- and cheminformatics platform information. TIP's seamless integration between structural data management technology and unique target-to-lead analysis capabilities enhances every stage of the discovery pipeline.

Global biopharmaceutical drug patents and generic entry business intelligence. Anticipate future budget needs and proactively find generic sources. Examine past successes of patent challengers to identify research paths for competitors. Inform portfolio management decisions on future drug development. Predict brand drug patent expiration, identify generic supplier, and prevent overstocking of branded drugs. Get formulation and manufacturing information. Identify final formulators, repackagers and relabelled.

Genospace understands that genomics is driving precision medicine development, but scaling its delivery remains a challenge. We are here to help. Our platform makes biomedical data meaningful, accessible and easy to use for everyone, especially those at the frontlines of care delivery. Your clinicians and researchers will have the information they need in order to make informed decisions. Join us in our mission to leverage high-dimensional molecular data to improve patient outcomes and accelerate drug discovery and research. For drug development and research, large-scale population data is essential. Genospace platform allows you to conduct cohort-driven analyses that will inform your research activities. We are experts in clinical trial research. Genospace allows you to quickly accrue patients by matching fragmented patient data with complex trial criteria. The Genospace platform enables you to integrate genomic medicine into your mainstream clinical care.

CDD Vault allows you to intuitively organize chemical structures, biological study data, as well as collaborate with external or internal partners via a simple web interface. Start a free trial to see how easy it can be to manage drug discovery data. Tailored for You Affordable Scales with your project team Activity & Registration * Electronic Lab Notebook * Visualization * Inventory * APIs

Amazon Neptune is a fully managed graph database service that allows you to quickly and reliably build applications that can work with highly connected data sets. Amazon Neptune's core is a purpose-built graph database engine that can store billions of relationships and query the graph with only milliseconds latency. Amazon Neptune supports the popular graph models Property Graph, W3C's RDF, as well as their respective query languages Apache TinkerPop Gremlin, SPARQL. This allows you to quickly build queries that efficiently navigate large datasets. Neptune supports graph use cases like recommendation engines, fraud detection and knowledge graphs. It also powers network security and drug discovery.

Our reputation as thought leaders in the areas of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology is earned through the success our clients have found through their relationship with us. With over 20 years of experience, we have the ability to translate science into software that is easy to use. We also provide expert consulting support for drug discovery, clinical research, and regulatory submissions.

Software that will improve safety, traceability and integration of your Pharmacotechnics and Medicines Manufacturing Unit. PharmaSuite is not designed to be used by all pharmacy services. We have broken PharmaSuite into functional modules that allow you to manage different units in the most efficient manner. Management of the Pharmacotechnics and Drug Preparation units (parenteral mixtures). Management of parenteral nutrition.

Chemical Computing Group (CCG), has a strong reputation in collaborative scientific support. Our team of PhD-level scientists has offices in North America and Europe. They work closely with clients to provide support, hands-on training, and scientific advice on a wide variety of projects. CCG continues to develop new technologies through its team of scientists, mathematicians and software engineers as well as scientific collaborations with customers.

Altis Labs launches Nota, a clinical information platform that accelerates R&D for therapeutics. AI predicts patient outcomes based on imaging data, so sponsors can prioritize their most promising treatments. Nota allows researchers to access imaging biomarkers and speed up R&D by operationalizing clinical trial imaging data. Altis' cloud software platform powered with deep learning allows biopharma to incorporate comprehensive outcomes predictions at the image level, patient level, and cohort-level in order to improve clinical trial designs and better anticipate clinical endpoints. These insights can accelerate drug development timelines and lower costs, while increasing the likelihood of success in clinical trials across therapeutic areas.

Kanteron Platform ingested digital pathology slides, medical images, and patient data from modalities and sequencers. It then provided a complete data toolkit for all hospital network teams. Precision Medicine at the point-of-care: Pharmacogenomics is used to prevent adverse medication events. It also incorporates data sources that have drug-gene interactions that were not previously available in easily accessible formats (e.g. Tables in a PDF document) and implementing the major Pharmacogenomic Databases (like PharmGKB or DGIdb, OpenTargets ...). This allows the user to refine their query to specific gene families, types, interactions, etc. Flexible AI allows you to choose the data set that is most appropriate for your use case and then apply it to your relevant medical images.

A series of carefully planned experiments can help you discover biological biomarkers, uncover disease mechanisms, find new drugs, or identify protein levels changes. It's easy to unlock the power of MS/Proteomics. This allows you to focus on the biological complexity and get closer to the moment for discovery. Our automated, repeatable workflow makes it easier to start experiments and reduce turnaround times. This gives you the flexibility and control to make decisions and act on them immediately. Our proteomics data processing workflow allows you to concentrate on biological insights and human to human collaboration. It is built to scale repeatedly. We have made repetitive and heavy processing easy to use the cloud, making it a seamless and enjoyable experience. Intelligent Proteomics seamlessly integrates complex moving parts to allow larger experiments to be processed, analyzed, and reported with ease.

Mantarray provides functional data in the early stages of preclinical testing for new medicines. Mantarray allows for parallel analysis of 3D engineered muscles tissues with adult-like functional profiles. This facilitates the discovery, safety and efficacy testing new therapeutics. The Mantarray Plate Kit has a 95% success rate in tissue formation and allows for reproducible engineered tissue production across 24 wells. The Mantarray platform is a flexible, easy-to-use, and scalable system that allows researchers to study 3D tissues in vitro from the comfort of their own laboratory. You will be among the first to receive this instrument. Mantarray's magnetic sensing technology detects the contraction of EMTs. This allows the user to measure the contractility in 24 tissues simultaneously, at a high throughput and in real-time. The software is user-friendly and eliminates the need for manual calculation of contractility.

ArgusLab is a program that allows you to molecular model, graphically, and design drugs for Windows operating systems. Although it is becoming a little outdated, it remains very popular. There have been more than 20,000 downloads to date. ArgusLab can be downloaded for free. You don't have to sign anything. If you're teaching a class in which ArgusLab might be useful, you can print as many copies as necessary. You cannot redistribute ArgusLab to other websites or sources. You may link to this website on your own websites, however. ArgusLab is being port to the iPad in a low-key effort. I have also worked with Qt cross-platform development environment to support Mac, Linux, and PC.

R&D and manufacturing labs must be able to change and reconfigure on the fly in order to accelerate new discoveries and bring products to market quickly. Data management shouldn't be a problem. Thermo Scientific™, Nautilus LIMS™, for Dynamic Discovery and R&D Environments was developed in partnership with customers. It is highly configurable and flexible. It increases workflow efficiency, throughput, data reliability, and simplifies administration, sample traceability, and regulatory compliance.

Cleerly, a digital healthcare company, is changing the way that clinicians approach heart disease treatment. We create intelligent clinical technologies that help clinicians identify and define atherosclerosis sooner, so they can provide personalized, vital treatment plans for all patients. Atherosclerosis is plaque buildup in the heart's vessels. We do not use indirect markers like risk factors or symptoms to diagnose the disease. Our AI-enabled digital healthcare pathway makes it easier, faster, and more accurate to diagnose and report heart disease. This improves overall clinical and financial outcomes. Cleerly empowers providers by analyzing, characterizing and quantifying plaque types. This allows them to more accurately determine the risk of heart attacks and to develop a treatment plan for improving heart health.

These intricate, complex machines are proteins. They are the building blocks of all biological processes, not only in your body, but in every living being. They are the building blocks of all life. There are currently around 100 million distinct proteins. Many more are discovered every year. Each protein has a unique 3D shape, which determines how it functions and what it does. It is expensive and time-consuming to determine the exact structure of each protein. This means that we only have a small number of proteins in our database. This gap is rapidly growing and we need to be able to predict the structure of millions unknown proteins. This could help us not only tackle disease but also help us find new medicines more quickly. It may also help us unlock the mysteries of life.

Artificial intelligence transforms healthcare diagnosis Predictive analytics and AI are used to detect early-stage diseases and provide accurate diagnosis. Cloud-enabled AI platform to provide affordable and accessible healthcare. Endimension Technology, a startup in healthcare artificial intelligence, was founded at IIT Bombay. AI algorithms are developed to automatically detect abnormalities in medical scans and diagnose diseases. The founding team includes machine learning researchers, software engineers, and medical doctors from well-respected institutions. Our mission is to develop healthcare AI technology products that reduce misdiagnosis. AI to reduce the workload of radiologists Improve patient turnaround time

ChemDraw®, solutions have been able to provide powerful capabilities and integrations that allow you to quickly transform ideas and drawings into publications you are proud of. ChemOffice+ Cloud is a chemistry communication suite that transforms chemical drawings into chemical knowledge. It facilitates the management, reporting, and presentation of your Chemistry research. ChemOffice+ Cloud is a robust and comprehensive suite that was designed to simplify, facilitate, accelerate, and accelerate chemistry communication. The cloud-native ChemDraw Professional chemistry communication suite adds a powerful set to scientific research by adding a powerful set to the foundations. ChemOffice+ Cloud makes it much easier to create reports to communicate chemical research. Chemists can use ChemOffice+ cloud to create PowerPoint slides and manuscripts that are ready for presentation.

Patients around the globe suffer from complex diseases and have a wide range of symptoms. They all share one thing: Patients need faster access to safer and more effective treatments. Owkin's mission empowers researchers at hospitals, universities, as well as pharmaceutical companies to understand why drug efficacy differs from patient to patient, improve the drug development process, identify the best drug for the patient to improve treatment outcomes, and provide support to patients. Owkin Loop, the core of Owkin’s research platform, connects medical researchers to high-quality datasets from top academic research centers around world. Owkin Studio, Owkin Connect and Owkin Studio are the two main components of Owkin Software Stack. They power Owkin Loop. Owkin medical research collaborations include oncology, immunology, and cardiovascular diseases.

metaphactory converts your data into actionable, contextual and consumable knowledge. It also drives continuous decision intelligence. Intuitive interfaces that are intuitive and out-of-the box for searching, browsing, and exploring your Knowledge Graph. It is possible to create custom interfaces using low-code that allow business users to interact with the Knowledge Graph. Start small, iterate often, and add new use cases, data, and users as you go. Low-code platform for building applications and agile knowledge management.

Polyfins Technology Inc, a Silicon Valley startup, uses technologies such as Artificial Intelligence for dermatology problems. It combines mobility and the power of AI to offer a simple-to-use solution that is accessible to both patients and healthcare professionals. To improve access and accuracy of dermatology care in developing and developed countries. Our AI-enabled applications Eczemalesss and Tibot allow users to access high quality skincare information at home. EczemaLess, an AI-enabled app for people with Eczema, is available. It offers a single-stop solution to Eczema, including tracking Eczema severity and managing triggers. Learn what could be triggering your eczema. Evaluate which treatments are most effective for you. Find out the most common triggers, severity and care routine.

Augnito combines Speech Recognition AI power with mobility. With best-in-class accuracy, Augnito allows you to edit, format, or complete reports at the speed and ease of human speech. You can now access your personal templates and short forms from any computer, whether you're at work, at home, or on the road. This program is best suited for those who need to create detailed reports, such as radiology, histopathology, and surgical notes. You can also dictate your reports from anywhere around the world. Augnito can recognize different accents and pronunciations without any profile training. Augnito is built with the most advanced deep learning technology and has the entire language for medicine that covers 50+ sub-specialties and all the popular generic and drug names.

Healthcare needs can change quickly. Healthcare facilities must be able to adapt and respond quickly. Care.ai Smart Care Facility Opera Platform transforms healthcare facilities with AI-enabled automation. It improves healthcare processes, saves valuable times, reduces costs, and eases the burdens on care team members so they can concentrate on providing the best possible patient care. The care facility is monitored by a neural network of sensors that continuously learns from patient behaviors. The care facility becomes more intelligent and self-aware by collecting behavioral data over time. This allows it to automate many tedious tasks. Process improvements and optimization can be achieved by utilizing real-time operational and clinical insights into behavior and conditions.